AEZ.TO News 1.27 Aeterna Zentaris Inc. (AEZ.TO)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris Inc. (AEZ.TO) 1.27 $AEZ.TO

Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors
PR Newswire - Wed Apr 09, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company" today announced that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound. The poster, titled, "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T. Schuster and M. Teifel, was presented yesterday by Irene Seipelt, Ph. D., Director, Preclinical Development at Aeterna Zentaris, during a poster session at the American Association for Cancer Research Annual Meeting in San Diego, California.

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
PR Newswire - Fri Mar 28, 4:23PM CDT
All amounts are in US dollars

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
PR Newswire - Thu Mar 20, 3:30PM CDT
All amounts are in US dollars

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
CNW Group - Wed Mar 12, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time.

NASA Television Airs Departure of Commercial Cargo Ship from Space Station
Close-Up Media - Thu Feb 20, 12:18AM CST
NASA announced that Orbital Sciences' Cygnus cargo spacecraft, which delivered almost a ton-and-a-half of supplies and scientific experiments to the International Space Station in January, completes its month-long mission to the orbiting laboratory Tuesday, Feb. 18.

Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer
PR Newswire - Tue Feb 04, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company" today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH" receptors. The article, "Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)", Emons G., Gorchev G., Harter P., Wimberger P., Stähle A., Hanker L., Hilpert F., Beckmann M.W., Dall P., Gründker C., Sindermann H., Sehouli J., outlines results of this study which had been previously presented at the European Society of Gynaecological Oncology's ("ESGO" annual meeting in September 2011. The article is currently available at this link.

Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH
PR Newswire - Mon Feb 03, 6:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company" today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.

Aeterna Zentaris Inc concludes USD13.2m public offering
M2 - Wed Jan 15, 8:14AM CST
Canadian-based biopharmaceutical company Aeterna Zentaris Inc (NasdaqCM :AEZS) (TSX:AEZ) reported the completion of its public offering of 11.0m units for net proceeds of USD12.2m on Tuesday.

Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Tue Jan 14, 10:15AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced the closing of its previously announced public offering of 11.0 million units (the "Offering" generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.

Aeterna Zentaris Inc prices public offering of 11.0m units
M2 - Fri Jan 10, 6:52AM CST
Biopharmaceutical company Aeterna Zentaris Inc (TSX:AEZ) revealed on Thursday that it has priced its public offering of 11.0m units at a purchase price of USD1.20 per unit.

Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants
CNW Group - Thu Jan 09, 7:31AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the"Company" today announced the pricing of its previously announced public offering of 11.0 million units (the "Offering", with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of US$1.25 per share. Net proceeds from the Offering are expected to be approximately US$12.2 million, after deducting underwriting commissions and other expenses related to the Offering.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 22

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 126

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 51

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 5

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 18

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading

Top 5 Most Recently Viewed Articles

Fortune Brands' Strategic Moves for Growth and Innovation

Updated Category News Views 506

Fortune Brands Embraces Change for Future Growth Fortune Brands Innovations, Inc. (NYSE: FBIN), a leading innovation company committed to transforming spaces into havens, has announced pivotal changes aimed at enhancing its growth opportunities. These strategic moves reflect the company's dedication to innovation and efficiency as it positions itself for future success....

Continue Reading
Robert Webb's Insightful Stock Options Exercise at NHI

Updated Category News Views 97

Robert Webb Exercises Stock Options at National Health Investors Recently, an important SEC filing revealed that Robert Webb, a Board Member at National Health Investors (NHI), has exercised a significant number of stock options. Key Highlights: The latest Form 4 filing shows that Webb exercised stock options for 70,000 shares of NHI, amounting to a remarkable $1,585,550....

Continue Reading
Palantir Technologies Inc. Increases Investment in UK Defense

Updated Category News Views 271

Palantir Technologies Inc. Stock Update Recently, shares of Palantir Technologies Inc. (NASDAQ: PLTR) saw an increase of 1.58% in pre-market trading following the announcement of a substantial deal with the U.K. government. Strategic Investment in UK Defense This exciting new partnership involves Palantir committing up to £1.5 billion, equivalent to approximately $2...

Continue Reading
Investigation of Varonis Systems, Inc.: A Call to Investors

Updated Category News Views 165

Investigation into Varonis Systems, Inc. Edelson Lechtzin LLP, a well-respected national law firm, is actively investigating Varonis Systems, Inc. (NASDAQ: VRNS) due to potential violations of federal securities laws. This investigation arises from troubling allegations regarding the company's financial disclosures and communication with investors. Varonis Systems,...

Continue Reading
Error Notification on NAV Values in Wealth Invest Fund

Updated Category News Views 127

Error Notification Regarding NAV Values Nasdaq Copenhagen A/S Nikolaj Plads 6 1067 København K Important Information The latest update relates to incorrect NAV values published for the I&T Nordiske Aktier Large Cap division (ISIN: DK0061276656) of Investeringsforeningen Wealth Invest during a specific time frame. Details of the NAV Error This error occurred from 09:45 on...

Continue Reading